Moderna and Merck's mRNA cancer vaccine cuts melanoma recurrence or death risk by 42%, detailed data confirm
The personalized mRNA therapy met key Phase 3 endpoints, and the readout has reignited debate over the stock's valuation even as regulators review it in the US
inkl · +13 outlets
Pfizer halts development of closely watched weight-loss drug
The move removes one of the few remaining large-pharma challengers to Lilly and Novo Nordisk in the obesity market.
BusinessWorld Online · +7 outlets
Trump delivers Oval Office announcement on weight loss drug costs
The pricing deal is projected to save $64.3 billion over 10 years, with drug costs framed as a midterm election issue.
BusinessWorld Online · +13 outlets
Eli Lilly and Novo Nordisk to discount their weight-loss drugs as price war intensifies
Discounting by the two GLP-1 leaders signals a shift from supply constraints to competition on price and access.
BusinessWorld Online · +13 outlets
FDA lifts clinical hold on Aardvark's ARD-101 Prader-Willi study after new safety data
The cleared hold let shares rebound, though the stock has since swung on HERO exploratory data and shareholder lawsuits.
BioSpace · +14 outlets
Tango reports 82% tumor response rate for combo therapy in advanced pancreatic cancer
The company will advance to Phase 3 despite declining response rates over time in the ESMO presentation.
STAT · +11 outlets
FDA approves subcutaneous/on-body injector induction for Skyrizi in Crohn's disease
AbbVie gains a more convenient induction option for its blockbuster immunology drug in inflammatory bowel disease.
BioPharm International · +10 outlets
Novo Nordisk says obesity drug trial confirms weight loss; wins narrow US label expansion
The company reported CagriSema data and a buyback alongside the label update, with a hunger-drug trial stopped early.
BusinessWorld Online · +9 outlets
FDA grants Ultomiris accelerated approval for adults with primary IgA nephropathy
AstraZeneca's complement inhibitor expands into a rare kidney disease with no approved targeted therapies.
Pharmaceutical Executive · +14 outlets
Roche adds Hanmi Pharmaceutical's obesity drug candidate HM17321 to pipeline
Hanmi's next-generation obesity candidate, now named Zantrutide, gains a large-pharma partner via Genentech.
BigGo Finance · +6 outlets
Korea's first homegrown GLP-1 obesity drug Eppe set for Oct. 29 rollout
The launch marks Korea's entry into a GLP-1 market long dominated by Lilly and Novo Nordisk.
Korea JoongAng Daily · +1 outlets
Teva introduces the first generic GLP-1 for weight loss
A generic entrant could pressure pricing across the fast-growing obesity drug class.
BusinessWorld Online · +9 outlets
Biohaven shares soar as FDA accepts Vyglyxia resubmission
The regulatory acceptance revives a program whose prior rejection had weighed on the stock.
Seeking Alpha · +2 outlets
Drug price cap debate intensifies as DRL flags margin cap and Congress faces midterm pressure
Caps on trade margins, Medicare pricing negotiations, and patent lobbying are converging on the sector.
Legis1 · +2 outlets
MDMA-assisted therapy could get FDA approval as soon as January, advocate says
The psychedelic treatment faces a contentious regulatory review after a prior rejection.
New York Post · +14 outlets
GLP-1 boom in India, China and Brazil can create a $22 billion market, JPMorgan says
Emerging-market demand is viewed as the next major growth driver for obesity drugs.
Business Standard · +13 outlets
Roche reports 9M 2026 sales rise on strong drug demand and pipeline advances
The results underscore resilience in Roche's core pharma business as it refreshes its pipeline.
TradingView · +1 outlets
Beauty giants target 'Ozempic face' as obesity drug boom opens new market
Cosmetics firms are chasing demand tied to skin and muscle changes from GLP-1 use.
Reuters · +1 outlets